Trevi Therapeutics, Inc. (TRVI): History, Ownership, Mission, How It Works & Makes Money

Ever wondered about the companies pioneering treatments for chronic cough and other neurologically mediated conditions? Trevi Therapeutics, Inc. (TRVI), a clinical-stage biopharmaceutical company, is making strides with its investigational therapy, Haduvio™. With a market cap of $538 million as of April 11, 2025, and $107.6 million in cash, cash equivalents, and marketable securities at the end of 2024, how is Trevi positioning itself to address unmet needs in the biopharmaceutical landscape? Keep reading to explore Trevi Therapeutics' journey, its innovative approach, and its financial strategies.

Trevi Therapeutics, Inc. (TRVI) History

The history of Trevi Therapeutics is marked by significant milestones and strategic decisions that have shaped its evolution into a clinical-stage biopharmaceutical company focused on developing therapies for chronic pruritus and other chronic conditions. Here’s a detailed look at its journey:

Trevi Therapeutics, Inc. Founding Timeline

Year established

Trevi Therapeutics was established in 2011.

Original location

The company is headquartered in New Haven, Connecticut.

Founding team members

While specific names of all founding team members are not available in the provided search results, the company's leadership has been crucial to its development. Jennifer Good has served as President and CEO since 2011, playing a pivotal role in guiding the company through its various stages of growth and clinical development.

Initial capital/funding

Details on the initial capital and funding sources at the company's inception are not specified in the provided search results. However, Trevi Therapeutics has raised capital through multiple financing rounds and an initial public offering (IPO) to fund its clinical programs.

Trevi Therapeutics, Inc. Evolution Milestones

Trevi Therapeutics, Inc. Transformative Moments

• 2017 IPO: The IPO provided Trevi Therapeutics with the necessary capital to aggressively pursue clinical trials for Haduvio, marking a significant step in its development as a public company.
• 2020 Phase 2b/3 Trial Results: The failure of the Phase 2b/3 trial for Haduvio in prurigo nodularis was a critical turning point. It forced the company to reassess its strategy, leading to cost reductions and a refocus on other potential indications.
• 2024 Positive Phase 2 CANAL Study Data: The positive results from the Phase 2 CANAL study in IPF cough revitalized the company's prospects, demonstrating Haduvio's potential in treating cough associated with IPF and opening new avenues for development and potential partnerships.

To gain further insights into the company's financial standing, you might find this resource helpful: Breaking Down Trevi Therapeutics, Inc. (TRVI) Financial Health: Key Insights for Investors

Trevi Therapeutics, Inc. (TRVI) Ownership Structure

Trevi Therapeutics, Inc. features a mix of institutional, insider, and retail ownership, which influences its strategic direction and governance.

Trevi Therapeutics, Inc.'s Current Status

Trevi Therapeutics, Inc. is a publicly traded company, listed on the Nasdaq Global Market under the ticker symbol TRVI. This status allows it to raise capital through public offerings and subjects it to regulatory oversight by the Securities and Exchange Commission (SEC).

Trevi Therapeutics, Inc.'s Ownership Breakdown

The ownership of Trevi Therapeutics, Inc. is distributed among various types of shareholders. The following table provides an overview of the ownership breakdown:

Trevi Therapeutics, Inc.'s Leadership

The leadership team at Trevi Therapeutics, Inc. is responsible for the strategic direction and operational management of the company. Here are some key members:

• Thomas A. Sciascia: President, Chief Executive Officer, and Director
• Lisa Delfini: Chief Financial Officer
• Dr. Andrew му: Chief Medical Officer

These individuals, along with other members of the executive team, guide the company's efforts in developing and commercializing innovative therapies. More information on Trevi Therapeutics' investors can be found here: Exploring Trevi Therapeutics, Inc. (TRVI) Investor Profile: Who’s Buying and Why?

Trevi Therapeutics, Inc. (TRVI) Mission and Values

Trevi Therapeutics is dedicated to developing innovative treatments for chronic conditions, particularly those involving severe itching (pruritus). The company focuses on improving patients' lives by addressing unmet medical needs in chronic diseases.

Trevi Therapeutics' Core Purpose

Official mission statement

While Trevi Therapeutics does not have a single, explicitly stated official mission statement readily available in public filings or press releases, their core purpose is evident through their activities and focus. Their mission can be inferred as:

To develop and commercialize innovative therapies to alleviate chronic and debilitating conditions, with a primary focus on addressing severe pruritus and other unmet medical needs.

• Focus on Innovation: Trevi Therapeutics is committed to developing novel therapies and solutions for challenging medical conditions.
• Patient-Centric Approach: The company prioritizes the needs and well-being of patients suffering from chronic conditions, aiming to improve their quality of life.
• Addressing Unmet Needs: Trevi Therapeutics targets conditions with limited or inadequate treatment options, striving to provide effective solutions where they are lacking.

Vision statement

Similarly, an explicitly stated vision statement is not available. However, the vision of Trevi Therapeutics can be understood as:

To become a leading biopharmaceutical company recognized for its innovative therapies that transform the lives of individuals suffering from chronic and debilitating conditions, particularly severe pruritus.

• Leadership in Pruritus: Trevi Therapeutics aims to be a leader in developing treatments for pruritus associated with various chronic conditions.
• Expanding Therapeutic Pipeline: The company envisions expanding its pipeline to address other unmet medical needs beyond pruritus.
• Global Impact: Trevi Therapeutics seeks to make a global impact by providing its therapies to patients worldwide, improving healthcare outcomes on a broad scale.

Company slogan/tagline

Trevi Therapeutics does not have an official, widely publicized slogan or tagline. However, considering their focus and objectives, a possible tagline that encapsulates their mission could be:

'Relief Beyond the Itch: Innovating for Chronic Conditions.'

To gain more insights into Trevi Therapeutics, Inc., explore: Exploring Trevi Therapeutics, Inc. (TRVI) Investor Profile: Who’s Buying and Why?

Trevi Therapeutics, Inc. (TRVI) How It Works

Trevi Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing Haduvio™ (nalbuphine ER) to treat chronic pruritus, or chronic itch, and other chronic conditions.

Trevi Therapeutics, Inc.'s Product/Service Portfolio

Trevi Therapeutics, Inc.'s Operational Framework

Trevi Therapeutics operates primarily through the clinical development and potential commercialization of its lead product candidate, Haduvio™. Their operational framework involves several key stages:

• Research and Development: Conducting preclinical and clinical trials to evaluate the safety and efficacy of Haduvio™ in treating chronic pruritus and other conditions.
• Clinical Trials: Managing and executing clinical studies, including Phase 2 and Phase 3 trials, to gather data supporting regulatory submissions. In 2024, Trevi completed Phase 2b/3 clinical trial of Haduvio for the treatment of pruritus in adults with prurigo nodularis
• Regulatory Affairs: Preparing and submitting regulatory filings to the FDA and other regulatory agencies to seek approval for Haduvio™.
• Manufacturing and Supply Chain: Establishing partnerships for the manufacturing and supply of Haduvio™ to ensure product availability upon regulatory approval.
• Commercialization: Developing marketing and sales strategies to promote and distribute Haduvio™ to healthcare providers and patients, if approved.

Trevi Therapeutics, Inc.'s Strategic Advantages

Trevi Therapeutics' strategic advantages stem from its focus on addressing unmet medical needs in chronic conditions. Key advantages include:

• Targeted Therapeutic Approach: Developing Haduvio™ specifically for chronic pruritus, a condition with limited treatment options.
• Innovative Formulation: Utilizing an extended-release formulation of nalbuphine to provide sustained relief and improved patient compliance.
• Clinical Data: Demonstrating positive results in clinical trials, supporting the potential efficacy and safety of Haduvio™.
• Market Opportunity: Addressing a significant patient population with chronic pruritus, offering a substantial market opportunity upon regulatory approval.

Read more about the company here: Exploring Trevi Therapeutics, Inc. (TRVI) Investor Profile: Who’s Buying and Why?

Trevi Therapeutics, Inc. (TRVI) How It Makes Money

Trevi Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) for chronic pruritus, or chronic itch. As a clinical-stage company, Trevi Therapeutics primarily generates revenue through strategic collaborations, licensing agreements, and, potentially, future sales of its developed products, pending regulatory approval.

Trevi Therapeutics, Inc. Revenue Breakdown

As of April 2025, Trevi Therapeutics, Inc. primarily operates as a clinical-stage company without products on the market. Therefore, its revenue streams are limited to collaborations and licensing agreements. The future revenue streams are highly dependent on the successful development, regulatory approval, and commercialization of Haduvio.

Trevi Therapeutics, Inc. Business Economics

Trevi Therapeutics operates under a business model typical of clinical-stage biopharmaceutical companies. Key aspects of its business economics include:

• R&D Investment: A significant portion of its expenditure is allocated to research and development activities, particularly clinical trials for Haduvio.
• Partnerships: Strategic partnerships and collaborations are crucial for funding clinical trials and expanding the potential market reach.
• Intellectual Property: The company relies heavily on patents and proprietary technology to protect its assets and maintain a competitive advantage.
• Regulatory Milestones: Achieving regulatory milestones, such as FDA approval, is critical for unlocking future revenue streams.

Trevi Therapeutics, Inc. Financial Performance

Trevi Therapeutics' financial performance reflects its status as a development-stage company. Key points include:

• Cash Reserves: Monitoring cash reserves is vital to ensure sufficient funding for ongoing clinical trials and operations.
• Operating Expenses: Operating expenses mainly consist of R&D costs and general administrative expenses.
• Net Loss: As the company invests heavily in R&D, it typically reports a net loss, which is common for biotech firms in the clinical stage.

To gain more detailed insights into Trevi Therapeutics' financial health, you can explore this analysis: Breaking Down Trevi Therapeutics, Inc. (TRVI) Financial Health: Key Insights for Investors

Trevi Therapeutics, Inc. (TRVI) Market Position & Future Outlook

Trevi Therapeutics is navigating a challenging market landscape while focusing on the development of novel therapies for chronic cough and other pruritic conditions; the company's future hinges on the successful clinical development and commercialization of its lead candidate, Haduvio.

Competitive Landscape

The competitive landscape for Trevi Therapeutics is shaped by other pharmaceutical companies focusing on similar therapeutic areas. While specific, up-to-date market share data as of April 2025 is not available, understanding the general dynamics provides context.

Opportunities & Challenges

Trevi Therapeutics faces both opportunities and risks as it strives to bring new treatments to market.

Industry Position

Trevi Therapeutics is a development-stage pharmaceutical company focusing on therapies for chronic cough and pruritus. Its industry position can be further understood through the following points:

• Focus on Niche Markets: The company targets specific unmet needs within the chronic cough and pruritus markets.
• Clinical Development Stage: As a company without approved products, its value is heavily tied to the success of its clinical programs.
• Partnership Potential: Trevi may seek partnerships with larger pharmaceutical companies to support late-stage development and commercialization.

For more insights into the investors and ownership of Trevi Therapeutics, Inc., you can explore this profile: Exploring Trevi Therapeutics, Inc. (TRVI) Investor Profile: Who’s Buying and Why?